Foresee Pharmaceuticals (6576.TWO), a Taiwan and United States-based biopharmaceutical company, announced on Thursday that it has signed an exclusive license agreement with Intas Pharmaceuticals for the commercialisation of Foresee's novel FP-001 program, Leuprolide Mesylate Injectable Suspension ready-to-use subcutaneous six-month and three-month depot formulations (Camcevi) in the United States.

According to the terms of the collaboration, Foresee Pharmaceuticals will receive USD10m upfront, along with certain regulatory milestones and sales milestones payments having a combined value totalling up to USD207m and a share of the product revenue in the territory. Accord BioPharma, Inc, a United States affiliate of Intas, is to cover all commercialisation costs in the territory.

The company has not filed the three-month indication for Camcevi with the US Food and Drug Administration (FDA), which is under development by Intas and Foresee, the Section 505(b)(2) New Drug Application for the six-month Camcevi indication, is presently under review by the US FDA.